1 Min Read
March 1 (Reuters) - Audentes Therapeutics Inc
* Audentes Therapeutics - commencement of LUSTRO, study designed to characterize disease course in patients living with Crigler-Najjar syndrome Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.